metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-107 CLINICAL SPECTRUM OF METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DI...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(December 2024)
Full text access
P-107 CLINICAL SPECTRUM OF METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PATIENTS WITH ALTERED ANKLE-BRACHIAL INDEX (ABI) AND CARDIOVASCULAR (CV) RISK FACTORS.
Visits
14
Diana Karen Tapia Calderón1, Francisco Alejandro Félix Téllez1, Sergio Cerpa Cruz1, José Roberto Barrientos Ávalos1, José Antonio Velarde Chávez1, Eliana Carolina Morel Cerda1, Juan Manuel Aldana Ledesma1, Edgar Santino García Jiménez1, José Antonio Velarde Ruiz Velasco1
1 HOSPITAL CIVIL DE GUADALAJARA, Guadalajara, Jalisco, México
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

MASLD is the most common chronic liver disease (CLD) with a worldwide prevalence of 25%. It is defined as >5% steatosis without any other known liver disease. Cardiovascular disease (CVD) is the most common cause of death in MASLD. Due to its association with atherosclerosis and its coexistence with traditional CV risk factors (i.e. obesity, insulin resistance, diabetes mellitus, dyslipidemia and hypertension). ABI is a simple and non-invasive tool used to diagnose peripheral arterial disease (PAD), an ABI of ≤0.9 is diagnostic of PAD and has shown to be an independent risk factor for CV disease and CV mortality. Currently, borderline ABI (0.91-0.99) is recommended to be considered as a CV risk factor. Aim: To describe the frequency of MASLD and altered ABI in patients with traditional CV risk factors.

Patients / Materials and Methods

An observational, descriptive, and cross-sectional study was performed, we included adult patients with CV risk factors (18 to 70 years old). The sociodemographic characteristics, alcohol consumption, drug usage, smoking and anthropometric measurements (height, weight, BMI, waist, hip and neck circumference) were collected. ABI measurement was performed in all patients with a 8 mHz vascular doppler to classify patients as: Normal ABI (1.0-1.4), Altered ABI (≤0.9 or >1.4) and borderline ABI (0.91-0.99). Transient elastography (Fibroscan) was performed to determine steatosis and fibrosis stage. We excluded pregnant women, previously known CV disease, CLD or PAD. Descriptive statistics and comparative analysis were performed using SPSS version 24 software.

Results and Discussion

Sixty-eight patients with CV risk factors were included (48 female [70.6%] with a mean age of 47.38 years). Comorbidities were detected as follows: obesity in 52 patients (76.5%); dyslipidemia in 49 patients (72%); diabetes mellitus in 46 patients (67.6%); arterial hypertension in 35 patients (51.5%). Fifty-three patients had normal ABI (77.9%); altered ABI was found in 15 patients (22.1%). Sixty-one patients were found to have steatosis (89.7%), out of which 14 patients had fibrosis (22.9%). Comparison of both groups (altered vs. normal ABI) are presented in Table 1.

Conclusions

Patients with traditional CV risk factors showed a high rate of MASLD and similar altered ABI compared to previously described populations.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos